Key result
Open mitral valve replacement with the transcatheter Edwards SAPIEN XT valve in a native stenotic mitral valve resulted in patient death at 25 days due to left ventricular outflow tract obstruction.
Why the study?
Does open mitral valve replacement with a transcatheter Edwards SAPIEN XT valve on cardiopulmonary bypass provide a safe option for patients with a native stenotic mitral valve?
Case Report (n=1)
Does open mitral valve replacement with a transcatheter Edwards SAPIEN XT valve on cardiopulmonary bypass provide a safe option for patients with a native stenotic mitral valve?
Open mitral valve replacement with a transcatheter valve in a native stenotic mitral valve carries a significant risk of fatal left ventricular outflow tract obstruction.
Answers are grounded in this paper and cite their sources.
LVOT obstruction can prove fatal after transcatheter mitral implantation in native valves; leaves open optimal patient selection and sizing criteria.
A 73-year-old woman underwent open mitral valve replacement with the transcatheter Edwards SAPIEN XT valve (Edwards Lifesciences, Corp, Irvine, CA USA) on cardiopulmonary bypass in a native, stenotic mitral valve. Because of left ventricular outflow tract obstruction, the patient died 25 days after implantation. There are previous reports of transcatheter valve implantation in native mitral valve with procedural success. However, in one case report, the patient died 10 days postoperatively.
No takes yet. Share an insight, caveat, or question.
Dahle et al. (2016) conducted a case report in Native, stenotic mitral valve (n=1). Open mitral valve replacement with transcatheter Edwards SAPIEN XT valve was evaluated on Mortality. Open mitral valve replacement with the transcatheter Edwards SAPIEN XT valve in a native stenotic mitral valve resulted in patient death at 25 days due to left ventricular outflow tract obstruction.
Synapse has enriched 10 related papers. Consider them for comparative context: